Syncom Formulations Reports 58% Profit Jump in Q1 FY2026-27

Syncom Formulations Delivers Robust Q1 Performance, Anchored by Trust. The company has posted a notable rise in consolidated income and profitability for the quarter, driven by its commitment to an ethical, prescription-focused business strategy. Mumbai, 14 August 2026, Syncom Formulations (India) Limited (BSE: 524470 | NSE: SYNCOMF), a pharmaceutical firm holding WHO-GMP and ISO 9001:2015 certifications, announced solid financial results for the quarter ending 30 June 2026, highlighting healthy revenue gains and a marked increase in profitability compared to the same period last year.

Consolidated figures show total income reached Rs.133.36 crore for Q1 FY 2026-27, up from Rs.122.94 crore in the same quarter last year, representing an 8 per cent rise. Profit before tax climbed 59 per cent to Rs.32.25 crore, up from Rs.20.29 crore, while profit after tax saw a jump of roughly 58 per cent to Rs.24.85 crore, compared to Rs.15.75 crore previously. The company also reported an improvement in earnings per share, which rose to Rs.0.26 from Rs.0.17. Revenue from operations climbed to Rs.125.53 crore, up from Rs.116.90 crore, marking a growth of nearly 7 per cent.

The Board of Directors has proposed a final dividend of Rs.0.10 per equity share (face value Rs.1 each) for the financial year concluding 31 March 2026, pending shareholder approval at the upcoming Annual General Meeting. These results underscore the compounding success of a business strategy the company has maintained for decades: an ethical, prescription-driven approach rooted in enduring partnerships with the medical community, backed by reliable manufacturing standards and rigorous cost management.

Commenting on the performance, Mr. Ankit Kedarmal Bankda, Chairman & Whole-time Director, said, "This quarter reflects the strength of the foundation we have built quality manufacturing, an ethical prescription-led model, and the trust of the medical community we have served for decades. Our focus remains on responsible, sustainable growth and on making quality medicines accessible to every patient we can reach."

A Deep Domestic Footprint

Syncom maintains a robust domestic presence through six specialised divisions, backed by a field team of more than 1,000 medical representatives. This team ensures a comprehensive pan-India reach, working directly with doctors in fields such as gynaecology, fertility, gastroenterology, critical care and veterinary medicine. In the women's healthcare sector, the company’s Ovafresh and Ovafresh-M brands, part of the Cratus Evolve portfolio, are recognized as top-tier brands in the national IVF and gynaecology market. Additionally, the company’s generics and OTC division offers consumer brands like Megajoy, Asardar and Kabz All Fine, which are widely stocked in pharmacies nationwide. To maintain product integrity, a specialized cold chain network is utilized to deliver temperature-sensitive medications to patients.

A Growing International Presence

Having entered the global market in 2001, Syncom currently exports to more than 15 countries. The company holds product registrations and regulatory clearances from over 10 international regulatory authorities.

Manufacturing Backbone

Manufacturing operations are centralized at the company’s WHO-GMP approved facility in Pithampur, Madhya Pradesh. This modern, 2,50,000 sq. ft. plant is equipped to produce a wide range of forms, including tablets, capsules, liquid orals, injectables, ophthalmics and topical preparations. Syncom Formulations (India) Limited is publicly traded on the BSE and the National Stock Exchange of India, and maintains its registered office in Mumbai.